As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.
Continue Reading
Category: Biomedical Prevention Products
CONFERENCE REFLECTIONS: TWO CROI “ROOKIES” DRAW INSPIRATION FROM CROI AT 30
CROI is a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases, including HIV and AIDS. It was the 30th year of the conference, but our first time attending. In this post, we reflect on what we learned and how we might apply key takeaways to our work on MOSAIC.
Continue Reading
CHAMPIONING CHOICE IN A MULTI-PRODUCT HIV PREVENTION MARKET
New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.
Continue Reading
LOCAL PARTNERSHIPS: PREPARING TO SUPPORT SUSTAINED ACCESS AND EFFECTIVE USE OF HIV PREVENTION PRODUCTS
The success of efforts to introduce new pre-exposure prophylaxis (PrEP) methods for HIV prevention, such as the PrEP ring and injectable CAB PrEP, will also rely on local partners. That’s why one of MOSAIC’s five strategic objectives is dedicated to strengthening local partner capacity to design and implement high-quality product introduction activities and research.
Continue Reading
AIDS 2022 KEY TAKEAWAYS
For the MOSAIC project team, the AIDS 2022 conference set the stage for embracing the introduction of new biomedical HIV prevention products and generating evidence on how to support choice and effective use. We attended the conference virtually and took away three key messages that resonate with our work on MOSAIC.
Continue Reading
A NEW OPTION TO TRANSFORM HIV PREVENTION
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading
AIDS 2022 SCIENTIFIC WORKSHOP | OUR NEXT SHOT: EFFECTIVELY DELIVERING INJECTABLE CABOTEGRAVIR FOR PrEP
This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue Reading
SHE DECIDES: SUPPORTING PrEP DECISION-MAKING AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN A MULTI-PRODUCT PrEP MARKET
As we move toward a multi-product HIV prevention market, adolescent girls and young women must be empowered to choose an HIV prevention product that meets their needs.
Continue Reading
NOVEL HIV PREVENTION PRODUCTS: EXPANDING THE EVIDENCE FOR INTRODUCTION
When countries introduce novel HIV prevention products, such as the PrEP ring and injectable CAB PrEP, how will women decide which product to use, and what will influence those decisions?
Continue Reading
“THESE NEW PRODUCTS GIVE ME POWER AND CONTROL OVER MY LIFE AND HEALTH”: CELEBRATING CHOICE ON INTERNATIONAL WOMEN’S DAY
Today, we observe International Women’s Day, a day to celebrate the many achievements of women around the globe.
Continue Reading